Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who have been diagnosed with a type of blood cancer called large B-cell lymphoma (LBCL), confirmed by a laboratory test
- People whose doctor has planned treatment for them using one of two specific CAR-T cell therapies (Yescarta or Kymriah), which are commercially available
- People whose organs are functioning well enough, and who are physically well enough (as judged by the treating doctor), to receive standard CAR-T treatment
- People who are not already enrolled in another clinical trial for "bridging therapy" (a treatment given before CAR-T)
- People who have had a PET/CT scan, CT scan, or MRI showing at least one measurable area of disease, taken before the cell collection process (leukapheresis) for CAR-T manufacturing
- People whose side effects from previous treatments have settled to a level the treating doctor considers acceptable for trial participation
- People who are able to give informed consent and are willing to follow all study procedures for the full duration of the study
Who may not be able to join:
- People who are pregnant or breastfeeding
- People with a known allergy to energy drinks
- People with a history of inflammatory bowel disease
- People with type 1 diabetes, or who require insulin
- People with chronic kidney disease where kidney function (eGFR) is below 30 mL/min/1.73m²
- People who have a second, separate cancer for which they are currently receiving treatment, or which would make it difficult for doctors to assess how the lymphoma is responding to treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Elise Chong, MD, Abramson Cancer Center at the University of Pennsylvania
Phone: 215-615-4312
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and tolerability
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.